Author: Riede, O; Seifert, K; Oswald, D; Endmann, A; Hock, C; Winkler, A; Salguero, F J; Schroff, M; Croft, S L; Juhls, C
Title: Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine Document date: 2015_4_30
ID: 4eyn7pjq_2
Snippet: LEISHDNAVAX is a mixture of five MIDGE-Th1 vectors each encoding a different Leishmania antigen: KMP11, CPA, CPB, P74 (elongation factor 1-alpha) or TSA. 22 Antigen selection and sequence design followed a novel rational approach. In a series of animal experiments it was demonstrated that LEISHDNAVAX is immunogenic and effective against challenge with Leishmania donovani, the causative agent of VL. 22 The vaccine is aimed to be administered to hu.....
Document: LEISHDNAVAX is a mixture of five MIDGE-Th1 vectors each encoding a different Leishmania antigen: KMP11, CPA, CPB, P74 (elongation factor 1-alpha) or TSA. 22 Antigen selection and sequence design followed a novel rational approach. In a series of animal experiments it was demonstrated that LEISHDNAVAX is immunogenic and effective against challenge with Leishmania donovani, the causative agent of VL. 22 The vaccine is aimed to be administered to humans in both preventive and therapeutic settings.
Search related documents:
Co phrase search for related documents- causative agent and Leishmania donovani: 1
- causative agent and rational approach: 1
- causative agent and sequence design: 1, 2
- Leishmania antigen and MIDGE th1: 1
- Leishmania antigen and MIDGE th1 vector: 1
- novel rational approach and rational approach: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date